Spiriva Finds COPD Exacerbation Studies Can Be An Exasperating Experience
This article was originally published in The Pink Sheet Daily
Executive Summary
As competitors tout comparative data, Boehringer hopes a Nov. 19 advisory committee on its claim for reduction in exacerbations will lead to a broader label.
You may also be interested in...
Spiriva Safety Debate Pits Clinical Study Results Against Meta-Analysis
FDA also asks advisory panel to assess mixed efficacy results for BI's drug to reduce exacerbation of chronic obstructive pulmonary disease.
Spiriva Safety Debate Pits Clinical Study Results Against Meta-Analysis
FDA also asks advisory panel to assess mixed efficacy results for BI's drug to reduce exacerbation of chronic obstructive pulmonary disease.
Good Showing For Nycomed's COPD Drug Daxas
Reports in the Aug. 27 Lancet look good for the novel phosphodiesterase-4 inhibitor, under consideration by U.S. and EU regulators.